PDS Biotech (PDSB) surged 24% to a 37-week high after Phase 2 data showed therapy PDS01ADC delivered a 78% objective response rate in colorectal cancer. Two-year survival exceeded 80%, more than doubling the control group. CEO Frank Bedu-Addo said results support the immunotherapy for metastatic cancer with liver metastases.